Welcome to our dedicated page for Dare Bioscience SEC filings (Ticker: DARE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Daré Bioscience, Inc. filings document a women’s health biotechnology issuer with product and pipeline disclosures, operating-result updates, and capital-structure activity. Recent 8-K reports cover financial results, Regulation FD presentations, and unregistered sales tied to a Regulation A unit offering composed of Series A Convertible Preferred Stock and warrants to purchase common stock.
Proxy and governance filings describe annual meeting matters, director elections, executive compensation, equity awards, board classification, and stockholder voting procedures. The record also includes disclosure around offering statements, preferred-stock conversion terms, warrant exercise terms, and financing activity associated with advancing women’s health products and clinical programs.
Daré Bioscience, Inc. completed closings of its previously announced Regulation A unit offering. The company issued 50,000 Investor Units, each priced at $5.00, with each unit consisting of one share of Series A Convertible Preferred Stock and two Investor Warrants.
In total, Daré issued 50,000 shares of Series A Preferred Stock and Investor Warrants to purchase up to 100,000 shares of common stock. The offering is conducted under an offering statement on Form 1-A qualified by the SEC on April 1, 2026, with related offering circulars dated January 6, March 26, and May 14, 2026.
Daré Bioscience reported a Q1 2026 net loss of $3.0 million, improving from a $4.4 million loss a year earlier, on modest revenue of $152,455 from research and development services and royalties. Operating expenses fell significantly as research and development spending declined.
The company ended the quarter with $18.5 million in cash and cash equivalents and working capital of about $0.5 million, but most cash is tied to restricted grant funding. Management states there is substantial doubt about its ability to continue as a going concern over the next 12 months without additional capital.
Daré is pursuing a dual-path strategy in women’s health, combining traditional FDA product development with Section 503B compounding and consumer health offerings. To support operations, it is raising funds through a Regulation A preferred/warrant offering and an equity line with Lincoln Park, while also using royalty financing backed by XACIATO sales.
Daré Bioscience reported first quarter 2026 results, posting revenue of $152,455 and a net loss of $2,999,889, or $0.20 per share, compared to a $4,378,307 loss a year earlier. Revenue came mainly from research and development services and royalty income tied to Gates Foundation agreements.
Cash and cash equivalents were $18,519,784 and working capital was $540,124 as of March 31, 2026, both down from year-end 2025. Operating expenses decreased, with research and development spending falling sharply, aided by $3,500,000 of grant-related contra-R&D expense.
The company highlighted multiple upcoming catalysts, including anticipated first direct product revenue from Flora Sync LF5 in June 2026 and DARE to PLAY in the third quarter of 2026, as well as a second positive interim Data Safety Monitoring Board review from the Phase 3 Ovaprene contraceptive trial.
Daré Bioscience, Inc. completed multiple closings of its ongoing Regulation A unit offering. The company issued 195,010 Investor Units, each priced at $5.00 and consisting of one share of Series A Convertible Preferred Stock and two Investor Warrants to purchase common stock.
The completed closings on May 1, 4, 5 and 6, 2026 resulted in 195,010 shares of Series A Preferred Stock and Investor Warrants to purchase up to 390,020 shares of common stock. The offering is being conducted under an offering statement on Form 1-A qualified by the SEC on April 1, 2026.
Daré Bioscience, Inc. files its Form 10-K reporting a strategic shift to a dual-path commercial model that pursues FDA approvals and earlier market access via Section 503B compounding, plus consumer health product launches. The company began commercialization of DARE to PLAY sildenafil cream in December 2025 and expects sales and pharmacy dispensing to begin in Q2 2026. Pipeline priorities include a pivotal Phase 3 study of Ovaprene (monthly, hormone-free contraceptive), planned Phase 3 activity for Sildenafil Cream for FSAD, DARE-HRT1 intravaginal ring for menopause symptoms, and ARPA-H-funded development of DARE-HPV. The company disclosed 14,559,502 shares outstanding as of March 25, 2026 and an aggregate market value of non-affiliate shares of approximately $21,339,826 as of its most recent second fiscal quarter.
Daré Bioscience is asking stockholders to vote at its virtual 2026 annual meeting on June 11, 2026. Holders of 14,559,502 shares of common stock as of April 14, 2026 may attend and vote online.
Key items include electing two Class III directors, ratifying Haskell & White LLP as auditor, and advisory votes on executive pay and how often that say‑on‑pay vote should occur. Stockholders are also asked to approve a potential future issuance of common stock to Lincoln Park Capital Fund, LLC under Nasdaq rules, and to amend the 2022 Stock Incentive Plan to add 1,500,000 shares for equity awards.
The proxy details board composition, governance practices, ownership, and 2025 executive pay. In 2025, CEO Sabrina Martucci Johnson received total compensation of $801,081 and Chief Accounting Officer MarDee Haring‑Layton received $546,858, largely driven by salary and stock option grants.
Daré Bioscience, Inc. furnished an updated corporate presentation on April 22, 2026. The presentation was made available in the Investors section of the company’s website and attached as Exhibit 99.1 to this report.
The information in Item 7.01 and Exhibit 99.1 is provided under Regulation FD and is expressly stated as furnished, not filed, meaning it is not subject to certain Exchange Act liability provisions and is not automatically incorporated into other Securities Act or Exchange Act filings.
Daré Bioscience, Inc. completed a closing of its Regulation A offering, selling 20,000 Investor Units at an offering price of $5.00 per unit. Each Investor Unit consists of one share of Series A Convertible Preferred Stock and two Investor Warrants, each warrant exercisable for one share of common stock, for a total of up to 40,000 common shares underlying the warrants. The units were issued under an offering statement on Form 1-A that was most recently qualified by the SEC on April 1, 2026, together with an offering circular dated January 6, 2026 and an offering circular supplement dated March 26, 2026.
Daré Bioscience, Inc. reported a change in how its board of directors is classified. The six-member board is divided into three classes, with one class elected each year for a three-year term. To rebalance these classes, director Gregory W. Matz voluntarily resigned as a Class II director, whose term would have expired at the 2028 annual meeting, and was simultaneously reappointed as a Class III director, whose term will expire at the 2026 annual meeting. Mr. Matz and Sabrina Martucci Johnson, the other Class III director, will stand for re-election at the 2026 annual meeting of stockholders. The company stated that this step was taken solely to rebalance the three director classes, that Mr. Matz’s service is deemed continuous for all other purposes, and that his board committee assignments did not change.
Daré Bioscience, Inc. is soliciting proxies for its 2026 Annual Meeting of Stockholders to be held virtually on June 11, 2026. Key items for stockholder votes include election of two Class III directors; ratification of Haskell & White LLP as auditor; advisory votes on executive compensation and frequency; Nasdaq-required approval for potential future issuances to Lincoln Park Capital Fund, LLC; and an amendment to increase the 2022 Stock Incentive Plan by 1,500,000 shares. The record date for voting was April 14, 2026, when 14,559,502 shares were outstanding. The proxy materials explain voting methods, quorum and broker voting treatment and note that final results will be filed on Form 8-K.